Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma

Targeted Oncology

Volumn 7, Issue 4, 2012, Pages 247-251

  Neuhaus, Thomas ^a,b   Luyken, Joachim ^a  

^a Gait Lab Social Pediatric Centre Children's Clinic St Vincenz Hospital   (Germany)

^b St Vincenz Krankenhaus   (Germany)

Author keywords

Sorafenib; Thymic carcinoma; Thymoma; Tyrosine kinase inhibitor

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; SORAFENIB; SUNITINIB; VINCRISTINE;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; CHRONIC COUGH; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPTIC SHOCK; SKIN TOXICITY; THYMUS CANCER;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RECURRENCE; THYMOMA; THYMUS NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84874494197     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0235-8     Document Type: Article

References (34)

1. Engels EA (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(Suppl 4):S260-S265
2. Kim DJ, Yang WI, Choi SS et al (2005) Prognostic and clinical relevance of the World Health Organization schema for the classification of thymic epithelial tumors: a clinicopathologic study of 108 patients and literature review. Chest 127:755-761 (Pubitemid 40775502)
3. Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H, Masaoka A (2002) The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 94:624-632 (Pubitemid 34132289)
4. Strobel P, Bauer A, Puppe B, Kraushaar T, Krein A, Toyka K, Gold R, Semik M, Kiefer R, Nix W, Schalke B, Müller-Hermelink HK, Marx A (2004) Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 22:1501-1509 (Pubitemid 41103633)
5. Gadalla SM, Rajan A, Pfeiffer R, Kristinsson SY, Björkholm M, Landgren O, Giaccone G (2011) A population-based assessment of mortality and morbidity patterns among patients with thymoma. Int J Cancer 128:2688-2694
6. Masaoka A, Monden Y, Nakahara K, Tanioka T (1981) Follow-up study of thymomas with special reference to their clinical stages. Cancer 48:2485-2492 (Pubitemid 12228012)
7. Chen G, Marx A, Chen WH, Yong J, Puppe B, Stroebel P, Muller-Hermelink HK (2002) New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 95:420-429 (Pubitemid 34787609)
8. Davenport E, Malthaner RA (2008) The role of surgery in the management of thymoma: a systematic review. Ann Thorac Surg 86:673-684 (Pubitemid 351978021)
9. Venuta F, Rendina EA, Longo F, De Giacomo T, Anile M, Mercadante E, Ventura L, Osti MF, Francioni F, Coloni GF (2003) Long-term outcome after multimodality treatment for stage III thymic tumors. Ann Thorac Surg 76:1866-1872 (Pubitemid 37510495)
10. Huang J, Rizk NP, Travis WD, Seshan VE, Bains MS, Dycoco J, Downey RJ, Flores RM, Park BJ, Rusch VW (2007) Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134:1477-1483 (Pubitemid 350101590)
11. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91:2010-2015 (Pubitemid 32476364)
12. Schmitt J, Loehrer PJ Sr (2010) The role of chemotherapy in advanced thymoma. J Thorac Oncol 5(10 Suppl 4):S357-S360
13. Rajan A, Giaccone G (2010) Targeted therapy for advanced thymic tumors. J Thorac Oncol 5(10 Suppl 4):S361-S364
14. Loehrer PJ, Yiannoutsos CT, Dropcho S et al (2006) A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma (abstract #7079). J Clin Oncol 24:383s
15. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29:2060-2065
16. Strobel P, Hohenberger P, Marx A (2010) Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol 5(10 Suppl 4):S286-S290
17. Suzuki E, Sasaki H, Kawano O, Endo K, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 36:351-356 (Pubitemid 44043923)
18. Henley JD, Cummings OW, Loehrer PJ Sr (2004) Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol 130:222-224 (Pubitemid 38553631)
19. Farina G, Garassino MC, Gambacorta M, La Verde N, Gherardi G, Scanni A (2007) Response of thymoma to cetuximab. Lancet Oncol 8:449-450 (Pubitemid 46621774)
20. Palmieri G, Marino M, Salvatore M, Budillon A, Meo G, Caraglia M, Montella L (2007) Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 12:757-761 (Pubitemid 46852818)
21. Kurup A, Burns M, Dropcho S, Pao W, Loehrer PJ (2005) Phase II study of gefitinib treatment in advanced thymic malignancies (abstract #7068). J Clin Oncol 23:16s
22. Bedano P, Perkins S, Burns M et al. (2008) A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma (abstract #19087). J Clin Oncol 26s
23. Pan CC, Chen PC, Chiang H (2004) KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 202:375-381 (Pubitemid 38325248)
24. Giaccone G, Rajan A, Ruijter R, Smit E, van Groeningen C, Hogendoorn PC (2009) Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 10:1270-1273
25. Strobel P, Hartmann M, Jakob A, Mikesch K, Brink I, Dirnhofer S, Marx A (2004) Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 350:2625-2626 (Pubitemid 38758557)
26. Steele NL, Plumb JA, Vidal L, Tjørnelund J, Knoblauch P, Rasmussen A, Ooi CE, Buhl-Jensen P, Brown R, Evans TR, DeBono JS (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804-810 (Pubitemid 351231163)
27. Rajan A, Giaccone G (2011) Chemotherapy for thymic tumors: induction, consolidation, palliation. Thorac Surg Clin 21:107-114
28. Cimpean AM, Raica M, Encica S, Cornea R, Bocan V (2008) Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 190:238-245
29. Tomita M, Matsuzaki Y, Edagawa M, Maeda M, Shimizu T, Hara M, Onitsuka T (2002) Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 124:493-498
30. Strobel P, Bargou R, Wolff A, Spitzer D, Manegold C, Dimitrakopoulou- Strauss A, Strauss L, Sauer C, Mayer F, Hohenberger P, Marx A (2010) Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br J Cancer 103:196-200
31. Bisagni G, Rossi G, Cavazza A, Sartori G, Gardini G, Boni C (2009) Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 4:773-775
32. Li XF, Chen Q, Huang WX, Ye YB (2009) Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report. Med Oncol 26:157-160
33. Dişel U, Oztuzcu S, Beşen AA, Karadeniz C, Köse F, Sümbül AT, Sezer A, Nursal GN, AbalI H, OzyIlkan O (2011) Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. Lung Cancer 71:109-112
34. Cimpean AM, Ceauşu R, Encicǎ S, Gaje PN, Ribatti D, Raica M (2011) Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma. Int J Exp Pathol 92:340-344